China-based Arctic Vision has signed an agreement for the acquisition of the ophthalmic device business of MDCO Technology.
The transaction will integrate MDCO’s intraocular lens (IOL), implantable contact lens (Phakic Lens), and refractive device platforms into Arctic Vision’s global innovation framework for ophthalmic solutions.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The acquisition is expected to enhance Arctic Vision’s capabilities by combining advanced device engineering and manufacturing from MDCO with its existing research and development (R&D) in therapies.
This integration aligns with Arctic Vision’s strategy to expand its pipeline in areas with significant unmet needs in the ophthalmic sector.
Arctic Vision expects to build a portfolio, leveraging its R&D strengths in retinal, ocular surface, and neuro-ophthalmic areas alongside MDCO’s design and manufacturing expertise.
Following the transaction, MDCO will operate as a wholly owned subsidiary of Arctic Vision.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe combined group will maintain operations in three locations: Shanghai for biopharmaceutical research and regulatory affairs; Hangzhou for device R&D, manufacturing, and commercial management; and California for design and global collaboration.
MDCO specialises in cataract and myopia-correction solutions, leveraging materials-science and precision-moulding expertise developed over nearly two decades. Its Hangzhou site is the centre for operations, manufacturing, R&D, and commercial management.
Arctic Vision founder, chairman and CEO Dr Eddy Wu said: “This transaction represents a pivotal step for Arctic Vision’s long-term growth strategy.
“Through the integration of MDCO’s ophthalmic device platforms with Arctic Vision’s pharmaceutical innovation capabilities, we are establishing a truly comprehensive ophthalmic innovation ecosystem—one that integrates scientific excellence with advanced manufacturing and commercial scale.
“Looking ahead, we are building a company structurally prepared for broader global investment participation and future capital-market opportunities while expanding our ability to reach more patients and deliver greater impact across the ophthalmology community worldwide.”
